1:24

To set the scene, could you firstly tell me a bit about your backgrounds, and your current work?

5:05

What role do you predict induced pluripotent stem cells (iPSCs) will play in the future of cell therapy?

8:30

What are the key benefits of autologous versus allogeneic cell therapies?

14:06

What do you see as the biggest obstacles to successful iPSC-based allogeneic cell therapy development – and how can they be addressed?

20:02

What are the most important considerations for developing a successful cell therapy manufacturing process?

24:10

What is your key advice for making the change from autologous to allogeneic cell therapy development a practical reality?